TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan
· Delayed Price · Currency is TWD 9.41
-0.04 (-0.42%)
Apr 24, 2025, 1:30 PM CST
TPEX:4157 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 150.65 | 123.13 | 36.23 | 1,295 | 23.42 | Upgrade
|
| Revenue Growth (YoY) | 22.35% | 239.87% | -97.20% | 5426.95% | 15.30% | Upgrade
|
| Cost of Revenue | 16.13 | 11.45 | 3.74 | 12.72 | 4.04 | Upgrade
|
| Gross Profit | 134.52 | 111.69 | 32.49 | 1,282 | 19.39 | Upgrade
|
| Selling, General & Admin | 90.55 | 98.9 | 72.64 | 99.06 | 77.27 | Upgrade
|
| Research & Development | 166.07 | 187.48 | 237.52 | 283.28 | 249.44 | Upgrade
|
| Operating Expenses | 256.62 | 286.39 | 310.16 | 382.34 | 326.71 | Upgrade
|
| Operating Income | -122.1 | -174.7 | -277.67 | 899.46 | -307.32 | Upgrade
|
| Interest Expense | -1.42 | -1.14 | -0.85 | -0.24 | -0.6 | Upgrade
|
| Interest & Investment Income | 24.4 | 20.38 | 8.72 | 4.23 | 3.5 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -23.24 | -113.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 54.17 | -15.68 | 51.79 | -4.24 | 13.08 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.48 | 149.4 | 0.01 | 0.04 | - | Upgrade
|
| EBT Excluding Unusual Items | -44.47 | -21.73 | -218 | 876 | -404.38 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.55 | 165.22 | 0.3 | 0.08 | 0.43 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.08 | 0.01 | Upgrade
|
| Asset Writedown | -1.96 | - | -12.06 | - | -2.92 | Upgrade
|
| Pretax Income | -32.89 | 143.49 | -229.77 | 875.99 | -406.87 | Upgrade
|
| Income Tax Expense | 5.7 | 6.76 | 7.4 | 100.37 | -2.06 | Upgrade
|
| Net Income | -38.58 | 136.73 | -237.16 | 775.62 | -404.82 | Upgrade
|
| Net Income to Common | -38.58 | 136.73 | -237.16 | 775.62 | -404.82 | Upgrade
|
| Shares Outstanding (Basic) | 717 | 717 | 717 | 717 | 717 | Upgrade
|
| Shares Outstanding (Diluted) | 717 | 717 | 717 | 717 | 717 | Upgrade
|
| Shares Change (YoY) | 0.03% | 0.06% | -0.07% | 0.07% | 0.01% | Upgrade
|
| EPS (Basic) | -0.05 | 0.19 | -0.33 | 1.08 | -0.56 | Upgrade
|
| EPS (Diluted) | -0.05 | 0.19 | -0.33 | 1.08 | -0.56 | Upgrade
|
| Free Cash Flow | -173.62 | 3.57 | -24.66 | 618.83 | -247.56 | Upgrade
|
| Free Cash Flow Per Share | -0.24 | 0.01 | -0.03 | 0.86 | -0.34 | Upgrade
|
| Gross Margin | 89.29% | 90.70% | 89.69% | 99.02% | 82.77% | Upgrade
|
| Operating Margin | -81.05% | -141.88% | -766.41% | 69.48% | -1312.10% | Upgrade
|
| Profit Margin | -25.61% | 111.04% | -654.61% | 59.91% | -1728.37% | Upgrade
|
| Free Cash Flow Margin | -115.25% | 2.90% | -68.06% | 47.80% | -1056.95% | Upgrade
|
| EBITDA | -113.76 | -164.59 | -267.53 | 909.9 | -295.49 | Upgrade
|
| EBITDA Margin | -75.51% | -133.67% | - | 70.29% | - | Upgrade
|
| D&A For EBITDA | 8.34 | 10.11 | 10.14 | 10.44 | 11.83 | Upgrade
|
| EBIT | -122.1 | -174.7 | -277.67 | 899.46 | -307.32 | Upgrade
|
| EBIT Margin | -81.05% | -141.88% | - | 69.48% | - | Upgrade
|
| Effective Tax Rate | - | 4.71% | - | 11.46% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.